169 related articles for article (PubMed ID: 32955081)
21. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19.
Hu X; Xing Y; Jia J; Ni W; Liang J; Zhao D; Song X; Gao R; Jiang F
Sci Total Environ; 2020 Aug; 728():138812. PubMed ID: 32335406
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics and predictors of the duration of SARS-CoV-2 viral shedding in 140 healthcare workers.
Liu W; Liu Y; Xu Z; Jiang T; Kang Y; Zhu G; Chen Z
J Intern Med; 2020 Dec; 288(6):725-736. PubMed ID: 32959400
[TBL] [Abstract][Full Text] [Related]
23. Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses.
Glans H; Gredmark-Russ S; Olausson M; Falck-Jones S; Varnaite R; Christ W; Maleki KT; Karlberg ML; Broddesson S; Falck-Jones R; Bell M; Johansson N; Färnert A; Smed-Sörensen A; Klingström J; Bråve A
BMC Infect Dis; 2021 May; 21(1):494. PubMed ID: 34044758
[TBL] [Abstract][Full Text] [Related]
24. Symptomatic Infection is Associated with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study of 110 Children in Wuhan.
Lu Y; Li Y; Deng W; Liu M; He Y; Huang L; Lv M; Li J; Du H
Pediatr Infect Dis J; 2020 Jul; 39(7):e95-e99. PubMed ID: 32379191
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial.
Sayad B; Khodarahmi R; Najafi F; Miladi R; Mohseni Afshar Z; Mansouri F; Rahimi Z; Shirvani M; Salimi M; Vaziri S; Janbakhsh A; Khosravi Shadmani F; Bozorgomid A; Zamanian MH; Afsharian M
J Antimicrob Chemother; 2021 Jul; 76(8):2158-2167. PubMed ID: 34037760
[TBL] [Abstract][Full Text] [Related]
26. Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial.
Song JY; Yoon JG; Seo YB; Lee J; Eom JS; Lee JS; Choi WS; Lee EY; Choi YA; Hyun HJ; Seong H; Noh JY; Cheong HJ; Kim WJ
J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441840
[TBL] [Abstract][Full Text] [Related]
27. An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19.
Fu W; Liu Y; Liu L; Hu H; Cheng X; Liu P; Song Z; Zha L; Bai S; Xu T; Yuan S; Lu F; Shang Z; Zhao Y; Wang J; Zhao J; Ding L; Chen J; Zhang L; Zhu T; Zhang X; Lu H; Xu J
EClinicalMedicine; 2020 Oct; 27():100547. PubMed ID: 32984784
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics and potential factors for recurrence of positive SARS-CoV-2 RNA in convalescent patients: a retrospective cohort study.
Ao Z; Li Y; Wei J; Jiang J; Wang X; Zhang P; Liu Y; Yu H; Zhu L; Wang X; Hu Q; Duan J; Hu W; Zhang X; Wu G; Guo S
Clin Exp Med; 2021 Aug; 21(3):361-367. PubMed ID: 33543353
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of Viral Clearance and Antibody Production Across Age Groups in Children with Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Bahar B; Jacquot C; Mo YD; DeBiasi RL; Campos J; Delaney M
J Pediatr; 2020 Dec; 227():31-37.e1. PubMed ID: 32891640
[TBL] [Abstract][Full Text] [Related]
31. Virological characteristics and the rapid antigen test as deisolation criteria in immunocompromised patients with COVID-19: A prospective cohort study.
Kang SW; Kim JW; Kim JY; Lim SY; Jang CY; Chang E; Yang JS; Kim KC; Jang HC; Kim D; Shin Y; Lee JY; Kim SH
J Med Virol; 2023 Nov; 95(11):e29228. PubMed ID: 38009999
[TBL] [Abstract][Full Text] [Related]
32. The effects of Alpha-2a and Beta-1a Interferons on the Coronavirus disease 2019 prognosis.
Haghbin A; Ghaffari-Nazari H; Taghavi MR; Vakili V; Rastgou S; Khoshkhui M
Qatar Med J; 2023; 2023(2):10. PubMed ID: 38025320
[TBL] [Abstract][Full Text] [Related]
33. A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19.
Fu W; Liu Y; Xia L; Li M; Song Z; Hu H; Yang Z; Wang L; Cheng X; Wang M; Jiang R; Liu L; Mao X; Chen J; Ling Y; Zhang L; Yan J; Shan F; Steinhart C; Zhang X; Zhu T; Xu J; Lu H
EClinicalMedicine; 2020 Aug; 25():100478. PubMed ID: 32838238
[TBL] [Abstract][Full Text] [Related]
34. Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review.
Alamri RD; Elmeligy MA; Albalawi GA; Alquayr SM; Alsubhi SS; El-Ghaiesh SH
Int Immunopharmacol; 2021 Apr; 93():107398. PubMed ID: 33571819
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis.
Buchynskyi M; Kamyshna I; Lyubomirskaya K; Moshynets O; Kobyliak N; Oksenych V; Kamyshnyi A
Front Immunol; 2023; 14():1069894. PubMed ID: 36776844
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Effectiveness of Interferon-α2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience.
Kamyshnyi A; Koval H; Kobevko O; Buchynskyi M; Oksenych V; Kainov D; Lyubomirskaya K; Kamyshna I; Potters G; Moshynets O
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108051
[TBL] [Abstract][Full Text] [Related]
37. Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic Changes.
Dona AA; Sanchez JF; Palmer JM; Synold TW; Chiuppesi F; Thomas S; Caserta E; Singer M; Tandoh T; Chowdhury A; Krishnan A; Rosenzweig M; Diamond DJ; Rosen S; Pichiorri F; Dadwal S
J Immunol Sci; 2023; 7(1):9-27. PubMed ID: 36996290
[TBL] [Abstract][Full Text] [Related]
38. Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
Lee PH; Tay WC; Sutjipto S; Fong SW; Ong SWX; Wei WE; Chan YH; Ling LM; Young BE; Toh MPH; Renia L; Ng LF; Leo YS; Lye DC; Lee TH
Clin Transl Immunology; 2020; 9(7):e1160. PubMed ID: 32742654
[TBL] [Abstract][Full Text] [Related]
39. Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals.
Aiello TF; Puerta-Alcalde P; Chumbita M; Lopera C; Monzó P; Cortes A; Fernández-Avilés F; Suárez-Lledó M; Correa J; Ortiz-Maldonado V; Cuesta G; Martinez-Cibrian N; Esteve J; Marcos MÁ; Mensa J; Soriano A; Garcia-Vidal C
J Antimicrob Chemother; 2023 Jun; 78(6):1454-1459. PubMed ID: 37051877
[TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics associated with long-term viral shedding in patients with coronavirus disease 2019.
Zhou M; Yu FF; Tan L; Zhu YD; Ma N; Song LJ; Li Q; Liu Y; Zou Z; Xu TY; Yu C
Am J Transl Res; 2020; 12(10):6954-6964. PubMed ID: 33194085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
